1 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction[J].N Engl JMed, 1998;339(4):229-34
2 Poulter N.Coronary heart disease is a multifactorial disease[J]. Am J Hypertens, 1999;12(10pt2):92-5S
3 Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Wilson PW, Levy D.Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study[J].Arch Intern Med, 1999;159(18):2206-12
4 Thomas F, Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A.Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women[J].Eur Heart J, 2002;23(7):528-35
5 Sung BH, Izzo JL, Wilson MF.Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol [J].Am J Hypertens, 1997;10(6):592-9
6 Stern N, Grosskopf I, Shapira I, Kisch E, Isaacov A, Limor R, et al.Risk factor clustering in hypertensive patients:impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines[J].J Intern Med, 2000;248 (3):203-10
7 Vaughan CJ, Gotto AM, Basson CT.The evolving role of statins in the management of atherosclerosis[J].J Am Coll Cardiol, 2000;35(1):1-10
8 Maron DJ, Fazio S, Linton, Mac RF.Current perspectives on statin[J].Circulation, 2000;101(2):207-13
9 Goode GK, Miller JP, Heagerty AM.Hyperlipidaemia, hypertension, and coronary heart disease [J].Lancet, 1995;345 (8946):362-4
10 Straznicky NE, Howes LG, Lam W, Louis WJ.Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension[J].Am J Cardiol, 1995;75(8):582-6
11 Jarai Z, Kapocsi J, Farsang C, Detki K, Pados G, Sebestyen Z, et al.Effect of fluvastatin on serum lipid levels in essential hypertension[J].Orv Hetil, 1996;137(34):1857-9
12 Abetel G, Poget PN, Bonnabry JP.Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin).A pilot study[J]. Schweiz MedWochenschr, 1998;128(7):272-7
13 Borghi C, Gaddi A, Ambrosioni E.Improved blood pressure control in hypertensive patients treated with statins[J].J Am Coll Cardiol, 2001;37(suppl A):233A-4
14 Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP, et al.Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia[J].Hypertension, 1999;34(6):1281-6
15 Onolo G, Melis MG, Formato M, Angius MF, Carboni A, Brizzi P, et al.Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients[J]. Eur J Clin Invest, 2000;30(11):980-7
16 Velussi M, Cernigoi AM, Tortul C, Memi M.Atrovastatin for the management of type-2 diabetic patients with dyslipidemia.A mid-term (9-month) treatment experience[J].Diabetes Nutr Metab, 1999;12(6):407-12
17 Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA.Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril) [J].Am J Cardiol, 1999;83 (10):1497-9
18 Borghi C, Prandin MG, Costa FV, Baccheli S, Degli Esposti D, Ambrosioni E.Use of statins and blood pressure control in hypertensive patients with hypercholesterolemia[J].J Cardiovasc Pharmacol, 2000;35(4):549-55
19 D'Agostino RB, Kannel WB, StepaniansMND, Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension[J].Am J Cardiol, 1993;71 (1):82-7
20 Jiang J, Roman RJ.Lovastatin prevents development of hypertension in spontaneously hypertensive rats[J].Hypertension, 1997;30(4):968-74
21 Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al.HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species[J].Hypertension, 2001;137(6):1450-7
22 Laufs U, La Fata V, Plutzky J, Liao JK.Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors [J].Circulation, 1998;97(12):1129-35
23 Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, et al.The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals[J].Nat Med, 2000;6(9):1004-10
24 Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al.Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits[J].Atherosclerosis, 2001;154(1):87-96
25 Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hemandez G, Diaz C, et al.Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells [J].J Clin Invest, 1998;101(12):2711-9
26 Agostino V, Lorenzo G, Daniele V, Armando M, Stefano, Antonio S.Cerivastatin enhances endothelium-dependent vasodilation by restoring nitric oxide availability in essential hypertensive patients with mild hypercholesterolemia [J].Am J Hyper, 2002;15(suppl 1):A43
27 Strehlow K, Wassmann S, Bohm M, Nickenig G.Angiotensin AT1-receptor over-expression in hypercholeterolemia.[J] ANN Med, 2000;32(6):386-9
28 Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M.Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men [J].Circulation, 1999;100(21):2131-4
29 Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, et al.Downregulation of angiotensin Ⅱ type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells[J].Arteriosder Thromb Vasc Bil, 2001;21(12):1895-901 |
